TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells.
Accumulation of ubiquitin-positive, tau- and α-synuclein-negative intracellular inclusions of TDP-43 in the central nervous system represents the major hallmark correlated to amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitin-positive inclusions. Such inclusions have variably been described as amorphous aggregates or more structured deposits having an amyloid structure. Following the observations that bacterial inclusion bodies generally consist of amyloid aggregates, we have overexpressed full-length TDP-43 and C-terminal TDP-43 in E. coli, purified the resulting full-length and C-terminal TDP-43 containing inclusion bodies (FL and Ct TDP-43 IBs) and subjected them to biophysical analyses to assess their structure/morphology. We show that both FL and Ct TDP-43 aggregates contained in the bacterial IBs do not bind amyloid dyes such as thioflavin T and Congo red, possess a disordered secondary structure, as inferred using circular dichroism and infrared spectroscopies, and are susceptible to proteinase K digestion, thus possessing none of the hallmarks for amyloid. Moreover, atomic force microscopy revealed an irregular structure for both types of TDP-43 IBs and confirmed the absence of amyloid-like species after proteinase K treatment. Cell biology experiments showed that FL TDP-43 IBs were able to impair the viability of cultured neuroblastoma cells when added to their extracellular medium and, more markedly, when transfected into their cytosol, where they are at least in part ubiquitinated and phosphorylated. These data reveal an inherently high propensity of TDP-43 to form amorphous aggregates, which possess, however, an inherently high ability to cause cell dysfunction. This indicates that a gain of toxic function caused by TDP-43 deposits is effective in TDP-43 pathologies, in addition to possible loss of function mechanisms originating from the cellular mistrafficking of the protein.
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Claudia
C
Capitini
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Simona
S
Conti
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Michele
M
Perni
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Francesca
F
Guidi
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Roberta
R
Cascella
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Angela
A
De Poli
Department of Physics, University of Genoa, Genoa, Italy.
Amanda
A
Penco
Department of Physics, University of Genoa, Genoa, Italy.
Annalisa
A
Relini
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Cristina
C
Cecchi
Section of Biochemistry, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
Fabrizio
F
Chiti
D000682:Amyloid / Q000737:chemistry; D045744:Cell Line, Tumor; D002470:Cell Survival; D004268:DNA-Binding Proteins / Q000737:chemistry* / Q000502:physiology / Q000648:ultrastructure; D019286:Endopeptidase K / Q000737:chemistry; D004926:Escherichia coli; D006801:Humans; D002479:Inclusion Bodies / Q000648:ultrastructure; D018625:Microscopy, Atomic Force; D009447:Neuroblastoma; D010766:Phosphorylation; D011485:Protein Binding; D017433:Protein Structure, Secondary; D059748:Proteolysis; D014162:Transfection; D054875:Ubiquitination
D000682:Amyloid; D004268:DNA-Binding Proteins; D019286:Endopeptidase K